131 related articles for article (PubMed ID: 34916122)
1. An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans.
Dercle L; Zhao B; Gönen M; Moskowitz CS; Connors DE; Yang H; Lu L; Reidy-Lagunes D; Fojo T; Karovic S; Maitland ML; Oxnard GR; Schwartz LH
Eur J Cancer; 2022 Jan; 161():138-147. PubMed ID: 34916122
[TBL] [Abstract][Full Text] [Related]
2. Ethnic diversity in treatment response for colorectal cancer: proof of concept for radiomics-driven enrichment trials.
Dercle L; Yang M; Gönen M; Flynn J; Moskowitz CS; Connors DE; Yang H; Lu L; Reidy-Lagunes D; Fojo T; Karovic S; Zhao B; Schwartz LH; Henick BS
Eur Radiol; 2023 Dec; 33(12):9254-9261. PubMed ID: 37368111
[TBL] [Abstract][Full Text] [Related]
3. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Dohan A; Gallix B; Guiu B; Le Malicot K; Reinhold C; Soyer P; Bennouna J; Ghiringhelli F; Barbier E; Boige V; Taieb J; Bouché O; François E; Phelip JM; Borel C; Faroux R; Seitz JF; Jacquot S; Ben Abdelghani M; Khemissa-Akouz F; Genet D; Jouve JL; Rinaldi Y; Desseigne F; Texereau P; Suc E; Lepage C; Aparicio T; Hoeffel C;
Gut; 2020 Mar; 69(3):531-539. PubMed ID: 31101691
[TBL] [Abstract][Full Text] [Related]
4. Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway.
Dercle L; Lu L; Schwartz LH; Qian M; Tejpar S; Eggleton P; Zhao B; Piessevaux H
J Natl Cancer Inst; 2020 Sep; 112(9):902-912. PubMed ID: 32016387
[TBL] [Abstract][Full Text] [Related]
5. Outcome prediction in resectable lung adenocarcinoma patients: value of CT radiomics.
Choe J; Lee SM; Do KH; Kim S; Choi S; Lee JG; Seo JB
Eur Radiol; 2020 Sep; 30(9):4952-4963. PubMed ID: 32356158
[TBL] [Abstract][Full Text] [Related]
6. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
[TBL] [Abstract][Full Text] [Related]
7. Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?
Yang L; Dong D; Fang M; Zhu Y; Zang Y; Liu Z; Zhang H; Ying J; Zhao X; Tian J
Eur Radiol; 2018 May; 28(5):2058-2067. PubMed ID: 29335867
[TBL] [Abstract][Full Text] [Related]
8. CT-Based Radiomics Analysis Before Thermal Ablation to Predict Local Tumor Progression for Colorectal Liver Metastases.
Taghavi M; Staal F; Gomez Munoz F; Imani F; Meek DB; Simões R; Klompenhouwer LG; van der Heide UA; Beets-Tan RGH; Maas M
Cardiovasc Intervent Radiol; 2021 Jun; 44(6):913-920. PubMed ID: 33506278
[TBL] [Abstract][Full Text] [Related]
9. CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial.
Froelich MF; Heinemann V; Sommer WH; Holch JW; Schoeppe F; Hesse N; Baumann AB; Kunz WG; Reiser MF; Ricke J; D'Anastasi M; Stintzing S; Modest DP; Kazmierczak PM; Hofmann FO
Eur Radiol; 2018 Dec; 28(12):5284-5292. PubMed ID: 29882070
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation.
Maitland ML; Wilkerson J; Karovic S; Zhao B; Flynn J; Zhou M; Hilden P; Ahmed FS; Dercle L; Moskowitz CS; Tang Y; Connors DE; Adam SJ; Kelloff G; Gonen M; Fojo T; Schwartz LH; Oxnard GR
Clin Cancer Res; 2020 Dec; 26(24):6464-6474. PubMed ID: 32988968
[TBL] [Abstract][Full Text] [Related]
11. Dual-region radiomics signature: Integrating primary tumor and lymph node computed tomography features improves survival prediction in esophageal squamous cell cancer.
Lu N; Zhang WJ; Dong L; Chen JY; Zhu YL; Zhang SH; Fu JH; Yin SH; Li ZC; Xie CM
Comput Methods Programs Biomed; 2021 Sep; 208():106287. PubMed ID: 34311416
[TBL] [Abstract][Full Text] [Related]
12. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
[TBL] [Abstract][Full Text] [Related]
14. Non-invasive prediction of microsatellite instability in colorectal cancer by a genetic algorithm-enhanced artificial neural network-based CT radiomics signature.
Chen X; He L; Li Q; Liu L; Li S; Zhang Y; Liu Z; Huang Y; Mao Y; Chen X
Eur Radiol; 2023 Jan; 33(1):11-22. PubMed ID: 35771245
[TBL] [Abstract][Full Text] [Related]
15. Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer.
Woff E; Hendlisz A; Ameye L; Garcia C; Kamoun T; Guiot T; Paesmans M; Flamen P
J Nucl Med; 2019 Feb; 60(2):178-184. PubMed ID: 29959212
[TBL] [Abstract][Full Text] [Related]
16. 3'-Deoxy-3'-
Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
[TBL] [Abstract][Full Text] [Related]
17. Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer.
Abraham JP; Magee D; Cremolini C; Antoniotti C; Halbert DD; Xiu J; Stafford P; Berry DA; Oberley MJ; Shields AF; Marshall JL; Salem ME; Falcone A; Grothey A; Hall MJ; Venook AP; Lenz HJ; Helmstetter A; Korn WM; Spetzler DB
Clin Cancer Res; 2021 Feb; 27(4):1174-1183. PubMed ID: 33293373
[TBL] [Abstract][Full Text] [Related]
18. Radiomics analysis of pre-treatment [
van Helden EJ; Vacher YJL; van Wieringen WN; van Velden FHP; Verheul HMW; Hoekstra OS; Boellaard R; Menke-van der Houven van Oordt CW
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2307-2317. PubMed ID: 30094460
[TBL] [Abstract][Full Text] [Related]
19. Comparison of computed tomography imaging analyses for evaluation after chemotherapy in patients with colorectal cancer: a retrospective pooled analysis of six phase II clinical trials.
Hirose K; Oki E; Shimose T; Sakamoto S; Sasaki S; Jogo T; Hu Q; Tsuda Y; Ando K; Nakashima Y; Saeki H; Mori M
Int J Clin Oncol; 2019 Nov; 24(11):1397-1405. PubMed ID: 31332611
[TBL] [Abstract][Full Text] [Related]
20. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V
Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
